

Business Results for The First Quarter of FY2010

(Three-months period ended June 30, 2010)

Miraca Holdings Inc.

(August 9, 2010)

※ Amounts and ratios shown in this material have been rounded.
The sum of the individual amounts in the table do not always correspond to the total, because of rounding.

1



Consolidated Financial Results for 1Q/FY2010

(billion yen)

| | 1Q/FY2009 Results | 1Q/FY2010 Results | Y/Y Variation |
|------------------------------|----------------------|----------------------|---------------|
| Net sales | 37.50 | 41.40 | 3.90 10.4% |
| In Vitro Diagnostics | 8.14 | 8.22 | 0.08 1.0% |
| Clinical Lab Testing | 23.49 | 26.23 | 2.74 11.7% |
| Healthcare Related (*) | 5.87 | 6.95 | 1.08 18.4% |
| Operating(Op.) income | (**) 5.18 13.8% | (**) 6.08 14.7% | 0.90 17.4% |
| In Vitro Diagnostics | 2.04 25.1% | 2.30 28.0% | 0.26 12.7% |
| Clinical Lab Testing | 2.36 10.0% | 2.87 10.9% | 0.51 21.6% |
| Healthcare Related (*) | 0.81 13.8% | 0.90 12.9% | 0.09 11.1% |
| Ordinary income | 5.29 14.1% | 6.15 14.9% | 0.86 16.3% |
| Net income | 3.08 8.2% | (***) 3.11 7.5% | 0.03 1.0% |

(*) Segment name has been changed from "Others" to "Healthcare Related".


(**) Operating income of 5.18 billion yen for 1Q/FY2009 includes segmentation adjustment of -16 million yen.
Operating income of 6.08 billion yen for 1Q/FY2010 includes segmentation adjustment of 13 million yen.

(***) Extraordinary loss for 1Q/FY2010 increased to 0.86 billion yen, mainly due to loss on adjustment for changes of accounting standard for asset retirement obligations of 0.77 billion yen.

2

Miraca Group


- Significant increase in Net sales
- Op. income and Ordinary income reach a record-high
- Stable growth in all business segments



*Capital expenditure for 1Q/FY10: 2.56 bn yen (+1.18 bn yen, yoy)
 *Depreciation and amortization for 1Q/FY10: 2.30 bn yen (+0.19 bn yen, yoy)


In Vitro Diagnostics

- Slight increase in Net sales, Op. income increases 12.7% yoy



Clinical Lab Testing


- Net sales jumps 11.7% yoy, Op. income increases 21.6% yoy



1Q/FY2010 Segment Performance Review (year-on-year comparison)


1. In Vitro Diagnostics:

Marginal increase in Net sales, strong growth in Op. income



◆ Net sales: +0.08 bn yen

- Sales decline of influenza test kits: -0.4 bn yen
(Sales in FY2009 increased due to the pandemic of influenza)
- Strong CL reagents sales: +0.3 bn yen
- Sales increase at subsidiaries: +0.2 bn yen




◆ Op. income: +0.26 bn yen

- Increase in marginal profit: +0.16 bn yen
- Effect of reduction in expenses: +0.1 bn yen

1Q/FY2010 Segment Performance Review (year-on-year comparison)

2. Clinical Lab Testing:

Increase both in Net sales and Op. income



◆ Net sales: +2.74 bn yen

Effect of consolidation of JCL(*) : +2.38 bn yen

⇒ Sales increase excluding JCL: +0.36 bn yen


• Off-site testing: +0.14 bn yen

- Testing price decline was within our estimate

- Increase in volume of testing

• FMS/Branch lab: +0.22 bn yen

- Steady sales growth at the existing clients



◆ Op. income: +0.51 bn yen

- Increase in marginal profit: +1.76 bn yen

- Profit decline due to:

Increased general expenses: -0.45 bn yen

(Amortization of goodwill of JCL: -0.02 bn yen)


Increased personnel expenses: -0.8 bn yen

(*) Japan Clinical Laboratories, Inc.

1Q/FY2010 Segment Performance Review (year-on-year comparison)

3. Healthcare Related:

Stable growth both in Net sales and Op. income



Net sales +1.08 bn yen, Op. income +0.09 bn yen

● Clinical Trials:

Net sales +0.06 bn yen, Op. income +0.05 bn yen

- Slight increase in sales affected by delays of pharmaceutical projects

- Increase in profit generated by cost reduction

● Sterilizing:

Net sales +0.20 bn yen, Op. income +0.04 bn yen

- Higher sales at the existing clients contributed to sales increase

- Op. income increased by promotion of streamlining


● Preventive Medicine Related:

Net sales +0.82 bn yen, Op. income flat

- Increase in sales due to full consolidation of Care'x (+0.71 bn yen) and sales growth in corporate health check segment

- Weak sales and profit of infection prevention products

(Strong sales in FY2009 due to the pandemic of influenza)



Factors affecting Business Performance (M&A and Change of Accounting Standard)

■ Application of “Accounting Standards for Asset Retirement Obligations”

- Both operating income and ordinary income decreased by 16 million yen
- Income before income taxes and minority interests decreased by 782 million yen

■ Effect of consolidation of JCL (Date of transfer of shares: Apr.1, 2010)

- Sales of Clinical Lab Testing and Healthcare Related increased by 2.38 billion yen and 0.39 billion yen, respectively
- Goodwill on acquisition of JCL: 0.85 billion yen (amortized under the straight-line method over 10 years)
→ Amortization of goodwill for 1Q/FY2010 (0.02 billion yen) was offset by profit of JCL

■ Acquisition of Innogenetics

Fujirebio signed a definitive agreement to acquire 100% of shares of Innogenetics from Abbott (Jul. 20, 2010)

Innogenetics NV (Belgium)

- Business activities: Development and marketing of IVD products (mainly in field of infectious diseases and genetic testing), and bio-related funded research
- Consolidated sales: 6,325 million yen (FY Dec. 2009) (Exchange rate; 1EUR = 112yen)
- Purpose of acquisition: Acquiring intellectual properties and know-how especially in the infectious diseases area and strengthening of business base in Europe through the company's distribution channel

* The company is planned to be included in consolidated financial statement from the 2nd Half of FY2010 (Currently under consideration by European Commission)

⇒ Plan to estimate this impact on business performance by the end of 1st Half

7

FY2010 Forecast (Consolidated)

(billion yen)

| | 1Q/FY2010 (3mos.) Results | 1H/FY2010 (6mos.) Forecast | FY2010 (12mos.) Forecast |
|------------------------|--|--|--|
| Net sales | 41.40 | 80.85 | 161.7 |
| Op. income | 6.08 14.7% | 9.70 12.0% | 20.2 12.5% |
| Ordinary income | 6.15 14.9% | 9.90 12.2% | 20.5 12.7% |
| Net income | 3.11 7.5% | 5.35 6.6% | 11.6 7.2% |

Both 1st half forecast and full-year forecast stay unchanged.

As to the acquisition of *Innogenetics*, the timing of the closing is not fixed yet, and the impact on the Group's business performance has not been fully estimated yet. (We do not expect any other major factors that may affect business performance in and after 2Q/FY2010.)

8



Contact information:

Miraca Holdings Inc.

Phone: +81-3-5909-3337

Akira Uchida ar-uchida@miraca-holdings.co.jp
Manager, IR Public Relations Group

Kazumi Yokokawa km-yokokawa@miraca-holdings.co.jp
IR Public Relations Group

Harumi Tanaka hm-tanaka@miraca-holdings.co.jp
IR Public Relations Group

Disclaimer regarding forward-looking statement:

The performance forecast provided in this document is prepared by the management based on currently available information and various hypotheses and ideas including significant risks or uncertainties. Please be aware that the actual performance may turn out to be different from the forecast as a result of various contributing factors.

Factors affecting the performance include, among others, aggravation of the economic situation, fluctuation of the exchange rate, change of regulatory, statutory, and administrative requirements, delayed launch of new products, pressures from the product strategies of competitive companies, and decline of the sales potential of existing products.

